How Tigecycline Causes Liver Problems
Tigecycline, a glycylcycline antibiotic, can elevate liver enzymes (ALT, AST, alkaline phosphatase) in up to 25-30% of patients, with severe hepatotoxicity rare but documented in post-marketing reports. It disrupts mitochondrial function, inhibiting protein synthesis and leading to hepatocyte stress.[1][2]
Which Patients Face Higher Risk
Pre-existing liver disease (Child-Pugh B/C cirrhosis) doubles hepatotoxicity odds; tigecycline dosing requires reduction here, yet enzyme elevations still hit 40%.[1]
Obesity (BMI >30) correlates with 2-3x higher ALT spikes due to altered pharmacokinetics and fatty liver overlap.[3]
Elderly patients (>65) show 15-20% increased incidence from reduced clearance.[2]
Alcoholics or those with viral hepatitis (HBV/HCV) have amplified risk via additive cytochrome P450 inhibition.[1]
Drug Interactions That Worsen Liver Strain
Combining with valproic acid raises tigecycline levels 2-fold, spiking transaminases in 35% of cases.[4]
Warfarin or other CYP3A4 inhibitors prolong exposure, elevating hepatotoxicity by 1.5x.[2]
Concomitant statins or fibrates add oxidative stress, with case reports of acute liver failure.[1]
Treatment Factors Raising Concern
Doses >100 mg/day (off-label high-dose regimens for MDR infections) increase enzyme elevations to 40%.[3]
Prolonged therapy (>14 days) triples risk; weekly monitoring shows cumulative damage in 10-15%.[2]
IV administration without hydration heightens biliary sludge formation.[1]
Monitoring and When to Worry
Check LFTs at baseline, days 3-5, and weekly; discontinue if ALT >5x ULN or bilirubin >2x ULN with symptoms (jaundice, fatigue).[1][2] Severe cases resolve post-discontinuation in 80%, but 5% progress to failure needing transplant.[3]
[1]: Tigecycline Prescribing Information (FDA)
[2]: Hepatotoxicity Review - Clinical Infectious Diseases
[3]: DrugPatentWatch.com - Tigecycline Safety Data
[4]: Drug Interaction Database - Lexicomp